Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
261
Selective downregulation of SR Ca<sup>2+</sup> handling proteins and decreased SR Ca<sup>2+</sup> uptake in TG mice hearts.
Published 2015“…The V<sub>max</sub> of Ca<sup>2+</sup> uptake was obtained at pCa 5.5.…”
-
262
-
263
Decreased splicing efficiency in DENV infected cells.
Published 2016“…On the lower panel, increase or decrease retention of introns for each time point is shown.…”
-
264
-
265
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
266
-
267
-
268
-
269
-
270
-
271
Topical application of ATX inhibitor (S32826) decreases IOP in rabbits.
Published 2012“…Further, IOP in the drug treated eyes was significantly reduced as compared to IOP in the control eyes based on the Wilcoxon Rank Sum test of differences in median's (n = 9). C and D. Effects of 5 and 2 mM S32826 on IOP with a daily (single morning dose, 35 µl×2; n = 4) dose of drug application, respectively. …”
-
272
Decreased TORC1 activates HPK-1 to extend longevity.
Published 2017“…Representative images of <i>Phpk-1</i>::<i>HPK-1</i>::<i>GFP</i> neuronal expression in day 3 adult animals after treatment with control (A), <i>daf-2</i> (B), <i>rict-1</i> (C) and <i>daf-15</i> RNAi (D). …”
-
273
-
274
-
275
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
276
-
277
-
278
-
279
Decreased expression of genes related to cholesterol biosynthesis and lipogenesis in PCA.
Published 2012“…The results of the analysis for LPP are shown in 1A, for CCCA in 1B, for FFA in 1C and for TF in 1D. …”
-
280